These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15581386)

  • 21. Re: Chan et al. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 16: 1156 - 1162.
    Onalaja D; Jainer AK
    Int J Geriatr Psychiatry; 2002 Nov; 17(11):1076-7; author reply 1077. PubMed ID: 12404659
    [No Abstract]   [Full Text] [Related]  

  • 22. [Effectiveness and tolerance of zotepine in a double-blind comparison with perazine in schizophrenic patients].
    Dieterle DM; Müller-Spahn F; Ackenheil M
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():18-22. PubMed ID: 1683334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol.
    Hwang TJ; Lin SK; Lin HN
    J Formos Med Assoc; 2001 Dec; 100(12):811-6. PubMed ID: 11802520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapy of neuropsychiatric symptoms: opportunities, challenges and current prospects.
    Rabins PV; Lyketsos CG
    Nat Clin Pract Neurol; 2007 May; 3(5):239. PubMed ID: 17479071
    [No Abstract]   [Full Text] [Related]  

  • 25. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial.
    Petit M; Raniwalla J; Tweed J; Leutenegger E; Dollfus S; Kelly F
    Psychopharmacol Bull; 1996; 32(1):81-7. PubMed ID: 8927680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olanzapine for psychotic and behavioral disturbances in Alzheimer disease.
    Schatz RA
    Ann Pharmacother; 2003 Sep; 37(9):1321-4. PubMed ID: 12921516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of negative symptoms in schizophrenia with zotepine.
    Barnas C; Stuppaeck C; Unterweger B; Hinterhuber H; Fleischhacker WW
    J Clin Psychopharmacol; 1987 Oct; 7(5):370-1. PubMed ID: 2890673
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical efficacy of lamotrigine and changes in the dosages of concomitantly used psychotropic drugs in Alzheimer's disease with behavioural and psychological symptoms of dementia: a preliminary open-label trial.
    Suzuki H; Gen K
    Psychogeriatrics; 2015 Mar; 15(1):32-7. PubMed ID: 25516380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and neuroendocrine effects of zotepine--a new neuroleptic drug.
    von Bardeleben U; Benkert O; Holsboer F
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):28-34. PubMed ID: 2883678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zotepine in Huntington's disease.
    Bonelli RM; Niederwieser G; Lahousen T; Hofmann P
    Hum Psychopharmacol; 2003 Apr; 18(3):227-9. PubMed ID: 12672176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological treatment of the psychosis of Alzheimer's disease: what is the best approach?
    Madhusoodanan S; Shah P; Brenner R; Gupta S
    CNS Drugs; 2007; 21(2):101-15. PubMed ID: 17284093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Behavioral and psychological symptoms assessed with the BEHAVE-AD-FW are differentially associated with cognitive dysfunction in Alzheimer's disease.
    Ito T; Meguro K; Akanuma K; Meguro M; Lee E; Kasuya M; Ishii H; Mori E
    J Clin Neurosci; 2007 Sep; 14(9):850-5. PubMed ID: 17587584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of atypical antipsychotics in patients with Alzheimer's dementia. CATIE-AD-Study (Clinical Antipsychotic Trials of Intervention Effectiveness Alzheimer's Disease)].
    Förstl H
    Internist (Berl); 2007 Jun; 48(6):642-4. PubMed ID: 17497111
    [No Abstract]   [Full Text] [Related]  

  • 34. Assessment of pharmacological toxicity using serum anticholinergic activity in a patient with dementia.
    Hori K; Funaba Y; Konishi K; Moriyasu M; Hirata K; Oyamada R; Tominaga I; Inada T
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):508-10. PubMed ID: 16048459
    [No Abstract]   [Full Text] [Related]  

  • 35. Introduction: antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric patients.
    Madhusoodanan S
    Am J Geriatr Psychiatry; 2001; 9(3):283-8. PubMed ID: 11481137
    [No Abstract]   [Full Text] [Related]  

  • 36. Atypical antipsychotic drugs and Alzheimer's disease.
    Jockers-Scherübl MC; Hellweg R
    N Engl J Med; 2007 Jan; 356(4):416-7; author reply 417-8. PubMed ID: 17256186
    [No Abstract]   [Full Text] [Related]  

  • 37. ["Judicious" use of neuroleptic drugs in the treatment of behavioral symptoms in the course of Alzheimer disease].
    Riva E; Nobili A; Trecate F
    Recenti Prog Med; 1998 Nov; 89(11):598-603. PubMed ID: 9844448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of zotepine in treating psychotic patients with hyperuricaemia: a case series.
    Chen TT; Chen JY; Bai YM; Lin CC
    Int J Neuropsychopharmacol; 2006 Apr; 9(2):259-61. PubMed ID: 15963242
    [No Abstract]   [Full Text] [Related]  

  • 40. Effectivity of zotepine in refractory psychoses: possible relationship between zotepine and non-dopamine psychosis.
    Harada T; Otsuki S; Sato M; Wake A; Fujiwara Y; Kashihara K; Fukuda K
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):47-51. PubMed ID: 2883682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.